Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer von Kim, Seung Tae, Cristescu, Razvan, Bass, Adam J., Kim, Kyoung-Mee, Odegaard, Justin I., Kim, Kyung, Liu, Xiao Qiao, Sher, Xinwei, Jung, Hun, Lee, Mijin, Lee, Sujin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Lee, Hyuk, Choi, Mingew, Talasaz, AmirAli, Kang, Peter Soonmo, Cheng, Jonathan, Loboda, Andrey, Lee, Jeeyun, Kang, Won Ki

Volltext

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example von Sachs, Jeffrey R, Mayawala, Kapil, Gadamsetty, Satvik, Kang, Soonmo Peter, de Alwis, Dinesh P

Volltext

Pseudocirrhosis in a pancreatic cancer patient with liver metastases： A case report of complete resolution of pseudocirrhosis with an early recognition and management von Kang, Soonmo Peter, Taddei, Tamar, McLennan, Bruce, Lacy, Jill

Volltext

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors von Daud, Adil I, Ashworth, Michelle T, Strosberg, Jonathan, Goldman, Jonathan W, Mendelson, David, Springett, Gregory, Venook, Alan P, Loechner, Sabine, Rosen, Lee S, Shanahan, Frances, Parry, David, Shumway, Stuart, Grabowsky, Jennifer A, Freshwater, Tomoko, Sorge, Christopher, Kang, Soonmo Peter, Isaacs, Randi, Munster, Pamela N

Volltext

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products von YANG, Soonmo Peter, RATAIN, Mark J

Volltext

Programmed death-1 blockade in mismatch repair deficient colorectal cancer von Le, Dung T., Uram, Jennifer N., Wang, Hao, Bartlett, Bjarne, Kemberling, Holly, Eyring, Aleksandra, Azad, Nilofer Saba, Laheru, Dan, Donehower, Ross C., Crocenzi, Todd S., Goldberg, Richard M., Fisher, George A., Lee, James J., Greten, Tim F., Koshiji, Minori, Kang, SoonMo Peter, Anders, Robert A, Eshleman, James R., Vogelstein, Bert, Diaz, Luis A.

Volltext

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab von Hutchins, Beth, Starling, Gary C, McCoy, Mark A, Herzyk, Danuta, Poulet, Frederique M, Dulos, John, Liu, Liming, Kang, Soonmo Peter, Fayadat-Dilman, Laurence, Hsieh, Mark, Andrews, Christine L, Ayanoglu, Gulesi, Cullen, Constance, Malefyt, Rene de Waal, Kastelein, Robert A, Saux, Sabine Le, Lee, Julie, Li, Sophie, Malashock, Dan, Sadekova, Svetlana, Soder, George, van Eenennaam, Hans, Willingham, Aarron, Yu, Ying, Streuli, Michel, Carven, Gregory J, van Elsas, Andrea

Volltext

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study von Tabernero, Josep, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles S., Wyrwicz, Lucjan, Lee, Keun Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Castro Salguero, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez Freitas Melro, Goekkurt, Eray, Chao, Joseph, Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, SoonMo Peter, Shitara, Kohei

Volltext

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy von NUNES, Raquel A, XIAOCHUN LI, FRIEDMAN, Paula, HARRIS, Lyndsay N, SOONMO PETER KANG, BURSTEIN, Harold, ROBERTS, Lisa, CARNEY, Walter, BLACKWELL, Kimberly, RYAN, Paula, BORGES, Virginia, IGLEHART, J. Dirk

Volltext

KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma von Le, Dung T., Yoshino, Takayuki, Jäger, Dirk, Andre, Thierry, Bendell, Johanna C., Wang, Ruixue, Kang, SoonMo Peter, Koshiji, Minori, Diaz, Luis A.

Volltext

A pharmacogenetic study of vorinostat glucuronidation von Kang, Soonmo Peter, Ramirez, Jacqueline, House, Larry, Zhang, Wei, Mirkov, Snezana, Liu, Wanqing, Haverfield, Eden, Ratain, Mark J

Volltext

Triple negative breast cancer: current understanding of biology and treatment options von Kang, Soonmo Peter, Martel, Maritza, Harris, Lyndsay N

Volltext

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy von Kang, Soonmo Peter, Saif, Muhammad Wasif

Volltext

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? von Kang, Soonmo Peter, Saif, Muhammad Wasif

Volltext

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? von Kang, Soonmo Peter, Saif, Muhammad Wasif

Volltext

Global variation in CYP2C8–CYP2C9 functional haplotypes von Speed, William C, Kang, Soonmo Peter, Tuck, David P, Harris, Lyndsay N, Kidd, Kenneth K

Volltext

Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory... von Puzanov, Igor, Dummer, Reinhard, Schachter, Jacob, Pavlick, Anna C., Gonzalez, Rene, Ascierto, Paolo Antonio, Margolin, Kim Allyson, Hamid, Omid, Agarwala, Sanjiv S., Carlino, Matteo S., Utikal, Jochen, Lotem, Michal, Ribas, Antoni, Mohr, Peter, Roach, Charlotte M., Dolled-Filhart, Marisa, Li, Xiaoyun Nicole, Ebbinghaus, Scot, Kang, Soonmo Peter, Daud, Adil

Volltext

Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001 von Robert, Caroline, Joshua, Anthony M, Kefford, Richard, Joseph, Richard Wayne, Wolchok, Jedd D., Hodi, F. Stephen, Hamid, Omid, Weber, Jeffrey S., Gangadhar, Tara C., Dronca, Roxana Stefania, Patnaik, Amita, Zarour, Hassane M., Hwu, Wen-Jen, Hersey, Peter, Daud, Adil, Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scot, Kang, Soonmo Peter, Ribas, Antoni

Volltext

Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma von Joseph, Richard Wayne, Gangadhar, Tara C., Puzanov, Igor, Robert, Caroline, Hamid, Omid, Dummer, Reinhard, Ribas, Antoni, Mehnert, Janice M., Daud, Adil, Celentano, Kellie Ann, Lindia, Jill Ann, Chatterjee, Manash Shankar, Turner, David C., Mayawala, Kapil, Elassaiss-Schaap, Jeroen, de Alwis, Dinesh Prasad, Li, Xiaoyun Nicole, Ebbinghaus, Scot, Kang, Soonmo Peter, Kefford, Richard

Volltext

Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL) von Schadendorf, Dirk, Dummer, Reinhard, Hauschild, Axel, Robert, Caroline, Hamid, Omid, Daud, Adil, van den Eertwegh, Alfons JM, Cranmer, Lee D., O'Day, Steven, Puzanov, Igor, Schachter, Jacob, Blank, Christian U., Salama, April K., Loquai, Carmen, Mehnert, Janice M., Wang, Yang, Ebbinghaus, Scot, Kang, Soonmo Peter, Zhou, Wei, Ribas, Antoni

Volltext